Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Side Effects Make Viking’s Oral Obesity Drug a Tough Pill for Investors to Swallow

Viking Therapeutics’ obesity pill met weight reduction goals of its Phase 2 test, but gastrointestinal side effects led to high discontinuation rates. Even so, analysts see potential for a lower dose of the Viking drug as a maintenance therapy. The post Side Effects Make Viking’s Oral Obesity Drug a Tough Pill for Investors to Swallow appeared first on MedCity News.

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success (VKTX)

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock dip a buy. Click for my VKTX update.

Why Viking Therapeutics Stock Crashed Today @themotleyfool #stocks $VKTX

Key PointsViking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks.The pill is proving "safe and well-tolerated." However, one-fifth of participants in the study complained of the side effects and dropped out of Viking's clinical trial.10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after…

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.

Stock Market Live August 19: S&P 500 (VOO) Rally Still on Hold Pending Fed Talk

Live Updates Live Coverage Updates appear automatically as they are published. Viking De-horned 10:36 am Viking Therapeutics stock (Nasdaq: VKTX) tumbled more than 42% in morning trading after announcing results of a 13-week clinical trial of its new GLP-1 weight loss pill VK2735. Patients in the study lost an average of 12.2% of body weight over the course of the trial — but 20% of participants dropped out complaining of side effects. Rival…

Viking shares sink as obesity pill misses expectations in key study

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug.